Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 1 , ISSUE 1 ( January-June, 2011 ) > List of Articles


Immune Interventional Strategies against Chronic Infection Diseases and Cancers: Present Challenges and Road Map to Solution

Mamun Al-Mahtab

Citation Information : Al-Mahtab M. Immune Interventional Strategies against Chronic Infection Diseases and Cancers: Present Challenges and Road Map to Solution. Euroasian J Hepatogastroenterol 2011; 1 (1):5-13.

DOI: 10.5005/jp-journals-10018-1002

License: CC BY-NC 4.0

Published Online: 01-09-2010

Copyright Statement:  Copyright © 2011; The Author(s).


The therapeutic efficacy of antiviral therapy against chronic viral infections and anticancer strategy against cancers is not satisfactory. Most of the antiviral drugs cause reduction of viral replication in chronic virus-infected subjects, however, recovery or cure from diseases does not occur in most cases. Various types of therapeutic approaches, such as ablation of cancer tissues, use of anticancer drugs and radiation therapy, are applied to treat patients with cancers. But, recurrence of cancer is a formidable problem in clinics. Taken together, sustained control of virus replication in chronic viral carriers and control of cancer recurrence in cancer patients are two major challenges. It is now evident that although different factors are responsible for pathogenesis of chronic viral infections and cancers, almost all patients exhibit distorted antiviral and anticancer immune responses. Thus, a new field of treatment of these diseases by immune intervention has been emerged. Immune therapy against chronic viral infections and cancers are in their infancy and facing several challenges. These challenges will be discussed to provide a road map for development of clinically-acceptable and potent immune therapeutic approaches against these diseases, especially in the context of liver diseases.

PDF Share
  1. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006;80: 8236 2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
  2. T-cell dysregulation caused by chronic antigenic stress: The role of CMV in immunosenescence. Aging Clin Exp Res 2006;18:171-73
  3. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40
  4. Hepatitis B infection: Pathogenesis and management. J Hepatol 2000;32(Suppl 1):89-97
  5. Hepatitis B virus: Old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003;51: 761-85
  6. Management of hepatitis B 2000—summary of a workshop. Gastroenterology 2001;120:1828-53
  7. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51
  8. HIV-1 reverse transcriptase: A therapeutical target in the spotlight. Curr Med Chem 2006;13:313-24
  9. Strategies for immune therapy: Würzburg, Germany, 29 February-3 March 2004. Cancer Immunol Immunother 2004;53:755-58
  10. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 2004;4:569-76
  11. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005;19:17-26
  12. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80
  13. Protection or damage: A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection. Curr Opin Microbiol 2000;3:387-92. Immune Interventional Strategies against Chronic Infection Diseases and Cancers Euroasian Journal of Hepato-Gastroenterology, January-June 2011;1(1):5-13 13 EJOHG 15. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006;5:707-16
  14. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. Curr Pharm Des 2007;13:1975-88
  15. The polyepitope approach to DNA vaccination. Curr Opin Mol Ther 1999;1:10-15
  16. An HLAA2 polyepitope vaccine for melanoma immunotherapy. J Immunol 1999;163:4058-63
  17. Multicenter study group: Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34:917-21
  18. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol 2003;18:218-22
  19. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53
  20. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007;13:2392-99
  21. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 2004;23:97-113
  22. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001;106:255-58
  23. Dendritic cells and the control of immunity. Nature 1998;392:245-52
  24. Vaccine therapy for hepatitis B virus carrier. Curr Drug Targets Infect Disord 2004;4:93-101
  25. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrier. Int J Mol Med 2004;14:295-99
  26. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: Evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo. Immunobiology 2004;209:551-57
  27. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58
  28. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36
  29. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med 1999;189:1555-64
  30. Part I: Vaccines for solid tumours. Lancet Oncol 2004;5:681-89
  31. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 2007;47:60
  32. In vivo immunization by vaccine therapy following virus suppression by lamivudine: A novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-61
  33. Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: Present limitation and future scopes. Curr Med Chem 2006;13:3113-19.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.